{"id":6044,"date":"2025-03-19T16:53:58","date_gmt":"2025-03-19T13:53:58","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=6044"},"modified":"2025-03-19T16:53:58","modified_gmt":"2025-03-19T13:53:58","slug":"the-american-heart-association-aha-has-highlighted-several-strategies-for-managing-elevated-lipoproteina-lpa","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/the-american-heart-association-aha-has-highlighted-several-strategies-for-managing-elevated-lipoproteina-lpa\/","title":{"rendered":"The American Heart Association (AHA) has highlighted several strategies for managing elevated lipoprotein(a) [Lp(a)]"},"content":{"rendered":"
The American Heart Association (AHA) has highlighted several strategies for managing elevated lipoprotein(a) [Lp(a)], given its role as an independent risk factor for cardiovascular disease. While statins do not directly lower Lp(a)\u2014and may even cause a slight increase\u2014they remain essential for reducing LDL-C and overall cardiovascular risk.<\/div>\n
<\/div>\n
Key Strategies Highlighted by AHA:<\/div>\n
1. PCSK9 Inhibitors (Evolocumab, Alirocumab):<\/span><\/div>\n
\u2022 Can reduce Lp(a) by 25-30%.<\/span><\/div>\n
\u2022 Also effectively lower LDL-C and cardiovascular risk.<\/span><\/div>\n
2. Lipoprotein Apheresis:<\/span><\/div>\n
\u2022 Used in severe cases, especially for patients with very high Lp(a) and progressive cardiovascular disease.<\/span><\/div>\n
\u2022 Can reduce Lp(a) levels by 50-75% per session.<\/span><\/div>\n
3. Emerging RNA-based Therapies (Pelacarsen, Olpasiran):<\/span><\/div>\n
\u2022 Target Lp(a) production at the genetic level.<\/span><\/div>\n
\u2022 Clinical trials have shown reductions of 80% or more.<\/span><\/div>\n
4. General Cardiovascular Risk Reduction:<\/span><\/div>\n
\u2022 LDL-C lowering remains a priority, as high LDL-C combined with high Lp(a) further increases risk.<\/span><\/div>\n
\u2022 Lifestyle modifications (healthy diet, exercise, smoking cessation) are still recommended, though they do not significantly reduce Lp(a) levels.<\/span><\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n
Key Findings from the AHA 2024 Presentations on Lp(a)-Lowering Therapies<\/div>\n
<\/div>\n
Source: AHA 2024 Scientific Sessions; Published in JAMA<\/div>\n
<\/div>\n
1. Overview of New Lp(a)-Lowering Therapies<\/div>\n
\u2022 Two new drugs, zerlasiran (siRNA-based) and muvalaplin (oral agent), showed ~80% reduction in Lp(a) in Phase II trials.<\/span><\/div>\n
\u2022 Both drugs target apolipoprotein(a) [apo(a)], preventing Lp(a) formation.<\/span><\/div>\n
<\/div>\n
2. ALPACAR-360 Trial (Zerlasiran \u2013 siRNA Therapy)<\/div>\n
\u2022 Led by Steven Nissen, MD (Cleveland Clinic, OH).<\/span><\/div>\n
\u2022 Study Design:<\/span><\/div>\n
\u2022 178 patients with ASCVD and high Lp(a) randomized into different dosing regimens.<\/span><\/div>\n
\u2022 Follow-up: 36 weeks.<\/span><\/div>\n
\u2022 Key Results:<\/span><\/div>\n
\u2022 85.6% Lp(a) reduction at the highest dose (450 mg\/24 weeks).<\/span><\/div>\n
\u2022 Moderate LDL-C (-25% to -32%) and apoB (-10% to -15%) reductions.<\/span><\/div>\n
\u2022 Well tolerated: Main side effects included injection-site reactions, headache, and nasopharyngitis.<\/span><\/div>\n
<\/div>\n
3. KRAKEN Trial (Muvalaplin \u2013 Oral Therapy)<\/div>\n
\u2022 Led by Stephen Nicholls, MBBS, PhD (Monash University, Australia).<\/span><\/div>\n
\u2022 Study Design:<\/span><\/div>\n
\u2022 233 patients with ASCVD, diabetes, or familial hypercholesterolemia.<\/span><\/div>\n
\u2022 Muvalaplin (10 mg, 60 mg, 240 mg) vs. placebo for 12 weeks.<\/span><\/div>\n
\u2022 Key Results:<\/span><\/div>\n
\u2022 85.7% Lp(a) reduction (intact assay) at highest dose.<\/span><\/div>\n
\u2022 No significant adverse events or safety concerns.<\/span><\/div>\n
\u2022 First oral Lp(a)-lowering agent, addressing cost and patient preference issues with injectables.<\/span><\/div>\n
<\/div>\n
4. Clinical Need & Future Directions<\/div>\n
\u2022 Lp(a) is a strong genetic risk factor for ASCVD and aortic stenosis, affecting 1 in 5 people.<\/span><\/div>\n
\u2022 Current lipid-lowering therapies (statins, ezetimibe) do not reduce Lp(a) and may increase it slightly.<\/span><\/div>\n
\u2022 Major ongoing cardiovascular outcome trials:<\/span><\/div>\n
\u2022 Lp(a)HORIZON (Pelacarsen \u2013 2025)<\/span><\/div>\n
\u2022 OCEAN(a)-Outcomes (Olpasiran \u2013 2026)<\/span><\/div>\n
\u2022 ACCLAIM-Lp(a) (Lepodisiran \u2013 2029)<\/span><\/div>\n
<\/div>\n
5. Future Challenges<\/div>\n
\u2022 Defining the threshold for \u201ctoo high\u201d Lp(a) and when to intervene.<\/span><\/div>\n
\u2022 Expanding access to Lp(a) testing worldwide, as it is not widely covered by payers.<\/span><\/div>\n
<\/div>\n
Currently, no FDA-approved therapy specifically for lowering Lp(a) exists. While several drugs are in advanced clinical trials, including siRNA-based therapies (Pelacarsen, Olpasiran, Zerlasiran) and oral agents (Muvalaplin), they are not yet available for clinical use.<\/div>\n
<\/div>\n
The most advanced candidate, Pelacarsen (Ionis\/Novartis), is being evaluated in the Lp(a)HORIZON trial, with cardiovascular outcomes data expected in 2025. If successful, it could become the first FDA-approved treatment for Lp(a) reduction.<\/div>\n
https:\/\/www.tctmd.com\/news\/two-lpa-lowering-therapies-clear-bar-kraken-and-alpacar-360?utm_source=chatgpt.com<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

The American Heart Association (AHA) has highlighted several strategies for managing elevated lipoprotein(a) [Lp(a)], given its role as an independent risk factor for cardiovascular disease. While statins do not directly lower Lp(a)\u2014and may even cause a slight increase\u2014they remain essential for reducing LDL-C and overall cardiovascular risk. Key Strategies Highlighted by AHA: 1. PCSK9 Inhibitors […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-6044","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=6044"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6044\/revisions"}],"predecessor-version":[{"id":6045,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/6044\/revisions\/6045"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=6044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=6044"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=6044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}